Cefpodoxime proxetil - Generic Drug Details

What are the generic drug sources for cefpodoxime proxetil and what is the scope of patent protection?

Cefpodoxime proxetil is the generic ingredient in three branded drugs marketed by Sankyo, Aurobindo Pharma Ltd, Chartwell Rx, Sun Pharm Inds Ltd, Pfizer, Alkem Labs Ltd, Anda Repository, Aurobindo Pharma, and Sandoz, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for cefpodoxime proxetil. Nine suppliers are listed for this compound.

Summary for cefpodoxime proxetil

US Patents:	0
Tradenames:	3
Applicants:	9
NDAs:	12
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	5,920
Drug Prices:	Drug price trends for cefpodoxime proxetil
What excipients (inactive ingredients) are in cefpodoxime proxetil?	cefpodoxime proxetil excipients list
DailyMed Link:	cefpodoxime proxetil at DailyMed

See drug prices for cefpodoxime proxetil

Recent Clinical Trials for cefpodoxime proxetil

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Entasis Therapeutics	Phase 1
James Graham Brown Cancer Center	Early Phase 1
Julio Ramirez	Early Phase 1

See all cefpodoxime proxetil clinical trials

Pharmacology for cefpodoxime proxetil

Drug Class

Cephalosporin Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for cefpodoxime proxetil

J01DD	Third-generation cephalosporins
J01D	OTHER BETA-LACTAM ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for cefpodoxime proxetil

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	CEFPODOXIME PROXETIL	cefpodoxime proxetil	TABLET;ORAL	065462-002	May 28, 2008	AB	RX	No	Yes
Aurobindo Pharma	CEFPODOXIME PROXETIL	cefpodoxime proxetil	TABLET;ORAL	065370-001	Jun 11, 2007	AB	RX	No	No
Sankyo	BANAN	cefpodoxime proxetil	FOR SUSPENSION;ORAL	050688-002	Aug 7, 1992		DISCN	No	No

Market Dynamics and Financial Trajectory for CEFPODOXIME PROXETIL

Last updated: July 28, 2025

---

Introduction

Cefpodoxime Proxetil stands as a vital third-generation cephalosporin antibiotic, utilized primarily in the treatment of respiratory tract infections, urinary tract infections, and skin infections. Its favorable pharmacokinetics, broad-spectrum efficacy, and safety profile make it a significant drug within both developed and emerging markets. This article examines the evolving market landscape, competitive positioning, and financial prospects associated with Cefpodoxime Proxetil, providing critical insights for stakeholders seeking to understand the drug’s trajectory.

---

Market Overview

Global Market Size and Growth Trends

The global cephalosporin market, encompassing Cefpodoxime Proxetil, is projected to demonstrate robust growth over the next decade. According to [1], the overall antibiotic market is expected to reach USD 55 billion by 2030, with cephalosporins constituting a significant segment due to their broad-spectrum activity and favorable safety profile. The Middle East and Asia-Pacific regions are anticipated to exhibit the highest compound annual growth rates (CAGR), driven by increasing antibiotic consumption, rising healthcare infrastructure, and the prevalence of infectious diseases.

Key Drivers

• Rising Infectious Disease Burden: Increased prevalence of respiratory and urinary tract infections globally sustains demand for Cefpodoxime Proxetil.
• Growing Antimicrobial Resistance: The emergence of resistant strains prompts healthcare providers to prefer third-generation cephalosporins, including Cefpodoxime Proxetil.
• Expanding Healthcare Access: Improved healthcare infrastructure in developing nations facilitates broader distribution and prescription of antibiotics.
• Pharmaceutical Innovation: Development of novel formulations—such as dispersible tablets and fixed-dose combinations—enhances drug accessibility and compliance.

Regulatory Landscape

Regulatory approvals across key regions (FDA, EMA, and approvals in emerging markets) favor the continued availability and use of Cefpodoxime Proxetil. Patent protections typically last 8–10 years post-approval, but generic versions proliferate post-expiry, intensifying market competition [2].

---

Market Players and Competitive Dynamics

The market for Cefpodoxime Proxetil encompasses both branded and generic manufacturers. Prominent companies include Teva Pharmaceuticals, Sandoz, Lupin, and various regional players. The landscape is characterized by:

• Generics Dominance: Patent expirations have led to widespread generic manufacturing, exerting downward pricing pressure.
• Pricing Strategies: Companies leverage economies of scale, regulatory approvals, and supply chain efficiencies to maintain profitability.
• Formulation Diversification: Introduction of pediatric-friendly formulations and combination therapies enhances consumer appeal.
• Distribution Channels: Expanding presence in hospital formularies and retail pharmacies underpin sales volume growth.

Emerging Market Trends

In countries such as India, China, and Brazil, Cefpodoxime Proxetil is a cornerstone antibiotic, supported by government initiatives to improve antibiotic access. Local manufacturers benefit from lower production costs, amplifying competition and impacting margins for global players.

---

Financial Trajectory and Projections

Historical Financial Performance

While individual company financials vary, the broader antibiotic segment has experienced moderate growth, with some slowing due to regulatory and antimicrobial stewardship measures. Generic manufacturers report margins ranging from 10% to 15% on Cefpodoxime Proxetil, influenced by pricing pressure.

Forecasting Future Revenue Streams

The anticipated CAGR (approx. 4-6%) for Cefpodoxime Proxetil in the next five to ten years hinges on multiple factors:

• Market Penetration: Increasing adoption in developing economies.
• Regulatory Approvals: Entry into new markets or expanded indications.
• Product Innovation: Development of combination therapies to combat resistance.

Assuming a conservative CAGR of 5%, the global Cefpodoxime Proxetil market (estimated at USD 1 billion in 2022) could surpass USD 1.6 billion by 2030, delineating a steady but competitive growth landscape.

Price and Cost Dynamics

Price erosion remains a pressing concern, driven by generic competition. Manufacturers aiming for sustainable margins focus on local manufacturing efficiencies, patent strategies, and expanding indications.

Investment and R&D Outlook

Investments in formulation innovation, such as extended-release versions and novel combinations, optimize therapeutic outcomes and can command premium pricing in niche markets. However, R&D expenditures are limited by the generic nature of most products, focusing instead on manufacturing and compliance.

---

Challenges and Risks

• Antimicrobial Resistance: Global efforts to curb antibiotic misuse threaten to impose stricter prescribing guidelines, potentially reducing volumes.
• Regulatory Stringency: Stringent approval processes and post-marketing surveillance increase compliance costs.
• Market Saturation: The proliferation of generics constrains pricing power.
• Supply Chain Disruptions: Raw material shortages, especially of cephalosporin intermediates, could affect production continuity.

---

Opportunities for Growth

• Emerging Markets Expansion: Increasing healthcare access opens new demand avenues.
• Product Differentiation: Developing formulations with improved bioavailability or compliance features offers competitive advantages.
• Strategic Partnerships: Collaborations with regional manufacturers ensure broader distribution and localized support.

---

Key Takeaways

• Cefpodoxime Proxetil remains a crucial antibiotic with stable demand driven by infection prevalence.
• Market growth is primarily fueled by emerging economies, despite intense generic competition.
• Price pressures necessitate cost efficiencies and product differentiation for sustained profitability.
• Regulatory pathways and antimicrobial stewardship pose risks but also opportunities for approved new uses and formulations.
• Companies that innovate around formulations and expand into underserved markets will be better positioned for future revenues.

---

FAQs

1. What factors influence the pricing and profitability of Cefpodoxime Proxetil?
Price competition from generics, manufacturing costs, regional demand, and regulatory costs primarily influence profitability. Patents and formulation innovations can temporarily sustain higher prices.

2. How does antimicrobial resistance impact Cefpodoxime Proxetil markets?
Resistance development can reduce efficacy, leading to decreased prescription volume and prompting a shift to newer or combination antibiotics, thus affecting market share.

3. Are there new formulations or indications for Cefpodoxime Proxetil in development?
While primarily available in traditional formulations, research focuses on combination therapies and pediatric formulations to improve compliance and broaden use cases.

4. What regional markets present the greatest growth opportunities?
Emerging economies like India, China, and Brazil currently offer the highest potential due to expanding healthcare infrastructure and high infectious disease burden.

5. How do regulatory environments shape the future of Cefpodoxime Proxetil?
Stringent approval processes and post-marketing surveillance may limit rapid market expansion but also ensure safety and efficacy standards, fostering confidence among prescribers.

---

References

[1] MarketWatch. (2022). Global Antibiotics Market Overview.
[2] GlobalData. (2022). Cephalosporin Market Analysis and Forecasts.